ES2534634T3 - Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen - Google Patents
Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen Download PDFInfo
- Publication number
- ES2534634T3 ES2534634T3 ES09783167.1T ES09783167T ES2534634T3 ES 2534634 T3 ES2534634 T3 ES 2534634T3 ES 09783167 T ES09783167 T ES 09783167T ES 2534634 T3 ES2534634 T3 ES 2534634T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- phenyl
- linear
- alkyl
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos de fórmula (I),**Fórmula** y sales farmacéuticamente aceptables de los mismos, en donde R1 se selecciona de - H y CH3; R2 se selecciona de - H y alquilo lineal C1-C4; X es OH o un residuo de fórmula NHR3 en donde R3 se selecciona de - H, OH, alquilo C1-C5, cicloalquilo C3-C6, alquenilo C2-C5, alcoxi C1-C5; - alquilo lineal o ramificado C1-C6, cicloalquilo C3-C6, alquenilo C2-C6, fenilalquilo C1-C6, sustituido con un grupo carboxi (COOH); - un residuo de fórmula SO2R4 en donde R4 es alquilo C1-C2, cicloalquilo C3-C6, haloalquilo C1-C3; Y es un heteroátomo seleccionado entre: - S, O y N; Z es un resto seleccionado entre - halógeno, alquilo C1-C4 lineal o ramificado, alquenilo C2-C4, alquinilo C2-C4, alcoxi C1-C4, hidroxi, carboxilo, aciloxi C1-C4, fenoxi, ciano, nitro, amino, acilamino C1-C4, haloalquilo C1-C3, haloalcoxi C1-C3, benzoilo, alcanosulfonato C1- C8 lineal o ramificado, alcanosulfonamidas C1-C8 lineal o ramificada, alquil C1-C8 sulfonilmetilo lineal o ramificado. Siempre que dichos compuestos no sean: ácido (2R)-2-{4-[(4-trifluorometil-1,3-tiazol-2-il)amino]fenil}propanoico; ácido (2R)-2-{4-[(4-metil-1,3-tiazol-2-il)amino]fenil}propanoico; ácido (2R)-2-{4-[(4-terc-butil-1,3-tiazol-2-il)amino]fenil}propanoico; ácido (2R)-2-{4-[(4-trifluorometil-1,3-oxazol-2-il)amino]fenil}propanoico; ácido (2R)-2-{4-[(4-metil-1,3-oxazol-2-il)amino]fenil}propanoico; (2R)-2-(4-[(4-trifluorometil-1,3-tiazol-2-il)amino]fenil}propanamida.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164605 | 2008-09-18 | ||
| EP08164605A EP2166006A1 (en) | 2008-09-18 | 2008-09-18 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| PCT/EP2009/062109 WO2010031835A2 (en) | 2008-09-18 | 2009-09-18 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2534634T3 true ES2534634T3 (es) | 2015-04-27 |
Family
ID=40291117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09783167.1T Active ES2534634T3 (es) | 2008-09-18 | 2009-09-18 | Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8624036B2 (es) |
| EP (2) | EP2166006A1 (es) |
| JP (1) | JP5571669B2 (es) |
| CN (1) | CN102159558B (es) |
| AU (1) | AU2009294558B2 (es) |
| BR (1) | BRPI0918759A2 (es) |
| CA (1) | CA2737099C (es) |
| CY (1) | CY1116176T1 (es) |
| DK (1) | DK2346841T3 (es) |
| ES (1) | ES2534634T3 (es) |
| HR (1) | HRP20150395T1 (es) |
| IL (1) | IL211683A (es) |
| PL (1) | PL2346841T3 (es) |
| PT (1) | PT2346841E (es) |
| RU (1) | RU2520212C2 (es) |
| SI (1) | SI2346841T1 (es) |
| SM (1) | SMT201500098B (es) |
| WO (1) | WO2010031835A2 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2634185B1 (en) | 2012-03-02 | 2016-01-13 | Sareum Limited | TYK2 kinase inhibitors |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| JP6239118B2 (ja) * | 2013-09-03 | 2017-11-29 | サリウム リミテッド | 医薬化合物 |
| AR103399A1 (es) * | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| EP3117835A1 (en) * | 2015-07-14 | 2017-01-18 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment of certain urological disorders |
| EP3192504A1 (en) | 2016-01-15 | 2017-07-19 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| ES2893701T3 (es) * | 2016-01-15 | 2022-02-09 | Dompe Farm Spa | Inhibidores de IL-8 para su uso en el tratamiento de neuropatía periférica inducida por quimioterapia |
| EP3518898A4 (en) * | 2016-10-03 | 2020-06-17 | The Children's Medical Center Corporation | PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY |
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| EP3342407A1 (en) | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
| EP3409277A1 (en) * | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| EP3868369A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue |
| EP3868368A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| BR112022018294A2 (pt) | 2020-03-26 | 2023-01-10 | Dompe Farm Spa | Inibidores de cxcl8 para uso no tratamento de covid-19 |
| EP4008325A1 (en) | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP3884932A1 (en) | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP3907214A1 (en) * | 2020-05-04 | 2021-11-10 | Dompe' Farmaceutici S.P.A. | Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use |
| IL302553A (en) | 2020-11-05 | 2023-07-01 | Icahn School Med Mount Sinai | CXCR1/CXCR2 inhibitors for use in the treatment of myelofibrosis |
| EP4052702A1 (en) | 2021-03-04 | 2022-09-07 | Dompé farmaceutici S.p.a. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1051906A (en) * | 1973-10-24 | 1979-04-03 | Shionogi And Co. | Thiazole derivatives and production thereof |
| US4025528A (en) * | 1973-10-24 | 1977-05-24 | Shionogi & Co., Ltd. | Thiazole derivatives of benzoic and phenylalkanoic acids |
| JPS5537556B2 (es) * | 1973-12-27 | 1980-09-29 | ||
| JPS565747B2 (es) * | 1973-10-24 | 1981-02-06 | ||
| JPS5629871B2 (es) * | 1974-05-22 | 1981-07-10 | ||
| JPS62142168A (ja) * | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| IT1298214B1 (it) | 1998-01-28 | 1999-12-20 | Dompe Spa | Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche. |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| ITMI20012434A1 (it) | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| CA2474322A1 (en) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| SI1776336T1 (sl) * | 2004-03-23 | 2010-01-29 | Dompe Spa | Derivati 2-fenilpropionske kisline in farmacevtski sestavki, ki jih vsebujejo |
| PT2024329E (pt) * | 2006-05-18 | 2013-11-04 | Dompe Spa | (2r)-2-[(4-sulfonil)aminofenil]propanamidas e composições farmacêuticas que as contenham |
| WO2008075184A2 (en) * | 2006-12-19 | 2008-06-26 | Dompe' Pha.R.Ma S.P.A. | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them |
| DE602008005488D1 (de) * | 2007-10-18 | 2011-04-21 | Dompe Spa | (r)-4-(heteroaryl)phenylethylderivate und pharmazeutische zusammensetzungen damit |
-
2008
- 2008-09-18 EP EP08164605A patent/EP2166006A1/en not_active Withdrawn
-
2009
- 2009-09-18 EP EP09783167.1A patent/EP2346841B1/en active Active
- 2009-09-18 PL PL09783167T patent/PL2346841T3/pl unknown
- 2009-09-18 ES ES09783167.1T patent/ES2534634T3/es active Active
- 2009-09-18 CA CA2737099A patent/CA2737099C/en active Active
- 2009-09-18 DK DK09783167.1T patent/DK2346841T3/en active
- 2009-09-18 JP JP2011527334A patent/JP5571669B2/ja active Active
- 2009-09-18 SI SI200931170T patent/SI2346841T1/sl unknown
- 2009-09-18 WO PCT/EP2009/062109 patent/WO2010031835A2/en active Application Filing
- 2009-09-18 AU AU2009294558A patent/AU2009294558B2/en active Active
- 2009-09-18 CN CN200980136860.5A patent/CN102159558B/zh active Active
- 2009-09-18 BR BRPI0918759A patent/BRPI0918759A2/pt not_active Application Discontinuation
- 2009-09-18 US US13/063,105 patent/US8624036B2/en active Active
- 2009-09-18 RU RU2011114992/04A patent/RU2520212C2/ru active
- 2009-09-18 PT PT97831671T patent/PT2346841E/pt unknown
-
2011
- 2011-03-10 IL IL211683A patent/IL211683A/en active IP Right Grant
-
2015
- 2015-04-08 CY CY20151100336T patent/CY1116176T1/el unknown
- 2015-04-09 HR HRP20150395TT patent/HRP20150395T1/hr unknown
- 2015-04-22 SM SM201500098T patent/SMT201500098B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011114992A (ru) | 2012-10-27 |
| CN102159558B (zh) | 2015-01-07 |
| PL2346841T3 (pl) | 2015-07-31 |
| AU2009294558B2 (en) | 2014-12-18 |
| EP2346841A2 (en) | 2011-07-27 |
| AU2009294558A1 (en) | 2010-03-25 |
| US20110207785A1 (en) | 2011-08-25 |
| EP2346841B1 (en) | 2015-01-14 |
| SI2346841T1 (sl) | 2015-07-31 |
| BRPI0918759A2 (pt) | 2015-12-29 |
| SMT201500098B (it) | 2015-07-09 |
| RU2520212C2 (ru) | 2014-06-20 |
| IL211683A (en) | 2014-01-30 |
| CA2737099C (en) | 2016-07-05 |
| EP2166006A1 (en) | 2010-03-24 |
| WO2010031835A3 (en) | 2010-06-24 |
| DK2346841T3 (en) | 2015-04-20 |
| WO2010031835A2 (en) | 2010-03-25 |
| CY1116176T1 (el) | 2017-02-08 |
| CN102159558A (zh) | 2011-08-17 |
| JP5571669B2 (ja) | 2014-08-13 |
| JP2012502957A (ja) | 2012-02-02 |
| PT2346841E (pt) | 2015-05-07 |
| HRP20150395T1 (hr) | 2015-06-19 |
| US8624036B2 (en) | 2014-01-07 |
| IL211683A0 (en) | 2011-06-30 |
| CA2737099A1 (en) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2534634T3 (es) | Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| PE20040087A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
| JP2017526636A5 (es) | ||
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| JP2012502957A5 (es) | ||
| AR047085A1 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR070531A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| RU2010133903A (ru) | Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты | |
| TW200736221A (en) | Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| RU2008135153A (ru) | Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20100256A1 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| CY1112649T1 (el) | Παραγωγο καρβαζολιου, διαλυτωμα αυτου ή φαρμακευτικως αποδεκτο αλας αυτου | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR057874A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| CO6251287A2 (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato -842 | |
| AR073369A1 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
| AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
| ES2655091T3 (es) | Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos | |
| CU20080165A7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR064760A1 (es) | Derivados de diazol como inhibidores de la eg-5 |